Syngene share strength reflects India's contract research opportunity
Times of India-15/09/2015 .Among the major India players, Syngene is the only pure CRO, and is estimated to have 40% of the market.
Syngene International Jumps 32% From Issue Price Within One Quarter
CNBC TV18- 15/09/2015. "Syngene International is targeting a growth of USD 250 million by FY2018", says Peter Bains CEO of the company) .
CROs Are Making Headlines -India’s drug discovery service sector is heating up
Contract Pharma-11/09/2015 .Syngene says it is intent on establishing new capabilities and augmenting existing services across the discovery & development continuum..